Knee injection options make more sense beside the simpler choices

Movement and support are still useful care

Gentle exercise may limit weakness while you skip the movement that brought on soreness. You can also discuss a brace, cane, useful weight loss, or medicine for swelling.

Try each home change through several ordinary days, unless it clearly makes you worse. If soreness isn't easing, returns often, or limits sleep or walking, arrange an exam.

When the knee settles, build activity back a little at a time. Don't try to make up every missed day at once.

Steroid and gel have different limits

Steroid medicine may settle an aching knee sooner, though the help often fades. Don't repeat it just because the next date has arrived.

In one study lasting two years, set steroid shots caused more cartilage loss without better relief than salt water. Ask your doctor to review benefit, safety, and surgery plans before each repeat.

The gel is thick liquid meant to act like the fluid inside your joint. In the largest review, it helped only a little more than salt-water shots with no active medicine.

Blood treatment and surgery answer different needs

Called platelet-rich plasma, PRP is blood spun down until more platelets sit in a smaller amount. Those blood parts carry growth factors, and the finished liquid is placed into your knee.

Trying to keep your natural knee working before replacement is called joint preservation. It doesn't rule out surgery if daily life stays limited.

At QC Kinetix, biologic therapies aren't surgery; they're procedures made from your blood, and after an exam the medical provider prepares concentrated PRP and places it in your knee during the visit. No choice suits every knee, so discuss more time, other care, and a surgery opinion too.

Sources

1. The 2019 ACR/Arthritis Foundation OA guideline makes a STRONG recommendation for intra-articular glucocorticoid injection in knee OA, alongside strong recommendations for exercise, weight loss, self-management, tai chi, cane use, bracing and NSAIDs; intra-articular steroid injection for HAND OA is only conditionally recommended.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis Rheumatol, 2020. DOI: 10.1002/art.41142.

2. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

3. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

4. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

5. A 2024 network meta-analysis of 48 studies (9,338 knees) at minimum 6-month follow-up ranked PRP first for pain and function (SUCRA 91.5), then BMAC (76.5) and hyaluronic acid (53.1), with corticosteroid (15.2) barely above placebo (13.7) at that time point.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

6. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database Syst Rev, 2025. DOI: 10.1002/14651858.CD013342.pub2.

7. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.

   U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff. U.S. Food and Drug Administration, 2020.

8. A 2024 systematic review of eight randomized trials (937 patients) found BMAC improved pain and function from baseline and beat hyaluronic acid on pain at 6 and 12 months, but the differences did NOT exceed the minimal clinically important difference, and no significant differences emerged against other injectables.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

9. A systematic review of eight studies (299 knees, mean follow-up 12.9 months) found BMAC improved 34 of 36 patient-reported outcomes from baseline, but all three comparative studies failed to show BMAC superior to other biologic injections or to placebo - a finding the authors weigh against its high cost.

   Keeling LE, et al. — Bone Marrow Aspirate Concentrate for the Treatment of Knee Osteoarthritis: A Systematic Review.. Am J Sports Med, 2022. DOI: 10.1177/03635465211018837.